Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 1/20 | 0.35 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.34 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | CACNA2D1 | P54289 | 9/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5948799 | 0.85 | PLA2G1B (0.41) | SLC22A1PLA2G1BPLA2G2ACACNA2D1SIGMAR1 | |
| SCHEMBL20614270 | 0.84 | KISS1R (0.34) | SLC22A1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL19501664 | 0.81 | PRMT3 (0.44) | SLC22A1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL441038 | 0.80 | SIGMAR1 (0.43) | SLC22A1PLA2G1BPLA2G2ACACNA2D1SIGMAR1 | |
| SCHEMBL4808961 | 0.80 | PRMT3 (0.50) | SLC22A1PRMT3CARM1PRMT6PRMT1 | |
| SCHEMBL20118869 | 0.79 | PLA2G1B (0.47) | PLA2G1BPLA2G2ASIGMAR1LMNA | |
| SCHEMBL21155222 | 0.79 | PLA2G1B (0.42) | PLA2G1BPLA2G2ACACNA2D1SIGMAR1LMNA | |
| SCHEMBL12478475 | 0.79 | EPHX1 (0.44) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL5948987 | 0.78 | SIGMAR1 (0.47) | SLC22A1PLA2G1BPLA2G2ACACNA2D1SIGMAR1 | |
| SCHEMBL20431090 | 0.77 | EPHX1 (0.48) | PRMT3CARM1PRMT6PRMT1PRMT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065960-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR RECEPTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | SLC22A1 2081/4885PRMT3 3866/4885CARM1 4595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.